SEMA3A and metabolic dysfunction-associated steatotic liver disease: Our study therefore warrants further research on the SEMA3A–NRP1 signaling pathway and its potential targets to attenuate early MASLD development as an entry point for progression to life-threatening hepatic and cardiometabolic sequelae.